JPWO2020162638A1 - 悪性腫瘍改善用組成物 - Google Patents
悪性腫瘍改善用組成物 Download PDFInfo
- Publication number
- JPWO2020162638A1 JPWO2020162638A1 JP2020571319A JP2020571319A JPWO2020162638A1 JP WO2020162638 A1 JPWO2020162638 A1 JP WO2020162638A1 JP 2020571319 A JP2020571319 A JP 2020571319A JP 2020571319 A JP2020571319 A JP 2020571319A JP WO2020162638 A1 JPWO2020162638 A1 JP WO2020162638A1
- Authority
- JP
- Japan
- Prior art keywords
- cells
- administered group
- nik
- drug
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims description 32
- 239000003814 drug Substances 0.000 claims abstract description 114
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims description 106
- 230000014509 gene expression Effects 0.000 claims description 73
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 57
- 208000034578 Multiple myelomas Diseases 0.000 claims description 56
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 claims description 33
- 235000021067 refined food Nutrition 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 230000032459 dedifferentiation Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 39
- 239000000126 substance Substances 0.000 abstract description 18
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 3
- 102000020233 phosphotransferase Human genes 0.000 abstract description 3
- 230000037406 food intake Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 184
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 85
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 47
- 230000030833 cell death Effects 0.000 description 43
- 206010025323 Lymphomas Diseases 0.000 description 38
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 34
- 230000028327 secretion Effects 0.000 description 34
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 33
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 33
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 230000003833 cell viability Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 230000001939 inductive effect Effects 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 25
- 230000004913 activation Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 24
- 102000003945 NF-kappa B Human genes 0.000 description 23
- 108010057466 NF-kappa B Proteins 0.000 description 23
- 206010061728 Bone lesion Diseases 0.000 description 22
- 230000006378 damage Effects 0.000 description 22
- 230000004614 tumor growth Effects 0.000 description 22
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 20
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 20
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 19
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 19
- 210000000988 bone and bone Anatomy 0.000 description 19
- IVWOUZKNCGFRBC-UHFFFAOYSA-N 1-methoxyxanthen-9-one Chemical compound O1C2=CC=CC=C2C(=O)C2=C1C=CC=C2OC IVWOUZKNCGFRBC-UHFFFAOYSA-N 0.000 description 18
- 229940043357 mangiferin Drugs 0.000 description 18
- 239000013641 positive control Substances 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- MPXAWSABMVLIBU-UHFFFAOYSA-N bellidin Chemical compound C1=CC(O)=C2C(=O)C3=C(O)C=C(O)C=C3OC2=C1O MPXAWSABMVLIBU-UHFFFAOYSA-N 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 230000037361 pathway Effects 0.000 description 16
- 240000006053 Garcinia mangostana Species 0.000 description 15
- 235000017048 Garcinia mangostana Nutrition 0.000 description 15
- 238000007906 compression Methods 0.000 description 14
- 230000006835 compression Effects 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 206010041541 Spinal compression fracture Diseases 0.000 description 13
- VEZXFTKZUMARDU-UHFFFAOYSA-N gamma-mangostin Chemical compound OC1=C(O)C(CC=C(C)C)=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3OC2=C1 VEZXFTKZUMARDU-UHFFFAOYSA-N 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 206010051151 Hyperviscosity syndrome Diseases 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 208000037147 Hypercalcaemia Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 230000000148 hypercalcaemia Effects 0.000 description 11
- 208000030915 hypercalcemia disease Diseases 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 208000017169 kidney disease Diseases 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 108700012434 CCL3 Proteins 0.000 description 10
- 102000000013 Chemokine CCL3 Human genes 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 229930182555 Penicillin Natural products 0.000 description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 229940100601 interleukin-6 Drugs 0.000 description 10
- 238000010899 nucleation Methods 0.000 description 10
- 229940049954 penicillin Drugs 0.000 description 10
- 229960005322 streptomycin Drugs 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- SGQWQUYTTYVSBS-UHFFFAOYSA-N 1,3,6,7-tetramethoxyxanthen-9-one Chemical compound COC1=C(OC)C=C2C(=O)C3=C(OC)C=C(OC)C=C3OC2=C1 SGQWQUYTTYVSBS-UHFFFAOYSA-N 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 102000008125 NF-kappa B p52 Subunit Human genes 0.000 description 8
- 108010074852 NF-kappa B p52 Subunit Proteins 0.000 description 8
- 206010060860 Neurological symptom Diseases 0.000 description 8
- 108091027967 Small hairpin RNA Proteins 0.000 description 8
- 208000005250 Spontaneous Fractures Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000004055 small Interfering RNA Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102000005747 Transcription Factor RelA Human genes 0.000 description 7
- 108010031154 Transcription Factor RelA Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000036210 malignancy Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 210000002997 osteoclast Anatomy 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 101710085938 Matrix protein Proteins 0.000 description 6
- 101710127721 Membrane protein Proteins 0.000 description 6
- 206010038357 Renal amyloidosis Diseases 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 206010041549 Spinal cord compression Diseases 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 201000007891 familial visceral amyloidosis Diseases 0.000 description 6
- ACRGTLGOYYTGNX-UHFFFAOYSA-N gamma-mangostin Natural products OC1=C(O)C=C2C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3OC2=C1 ACRGTLGOYYTGNX-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- CCEBJWKUMKKCDF-UHFFFAOYSA-N 1,3,5,6-tetrahydroxyxanthen-9-one Chemical compound OC1=CC=C2C(=O)C3=C(O)C=C(O)C=C3OC2=C1O CCEBJWKUMKKCDF-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 5
- 108010014632 NF-kappa B kinase Proteins 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- GNRIZKKCNOBBMO-UHFFFAOYSA-N alpha-mangostin Chemical compound OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3OC2=C1 GNRIZKKCNOBBMO-UHFFFAOYSA-N 0.000 description 5
- 206010002022 amyloidosis Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- ZHTQCPCDXKMMLU-UHFFFAOYSA-N norathyriol Chemical compound OC1=C(O)C=C2C(=O)C3=C(O)C=C(O)C=C3OC2=C1 ZHTQCPCDXKMMLU-UHFFFAOYSA-N 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 4
- KVZUCOGWKYOPID-UHFFFAOYSA-N 2,4,5-Trimethoxybenzoic acid Chemical compound COC1=CC(OC)=C(C(O)=O)C=C1OC KVZUCOGWKYOPID-UHFFFAOYSA-N 0.000 description 4
- JEPXZNXBEFYVOZ-UHFFFAOYSA-N 2,4,5-trimethoxybenzoyl chloride Chemical compound COC1=CC(OC)=C(C(Cl)=O)C=C1OC JEPXZNXBEFYVOZ-UHFFFAOYSA-N 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000006835 Lamins Human genes 0.000 description 4
- 108010047294 Lamins Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 4
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 210000005053 lamin Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000005937 nuclear translocation Effects 0.000 description 4
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229960004641 rituximab Drugs 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 3
- QFRCVVNEVUAGJC-UHFFFAOYSA-N COC1c(cccc2)c2Oc2c1cccc2 Chemical compound COC1c(cccc2)c2Oc2c1cccc2 QFRCVVNEVUAGJC-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- QTDMGAWIBXJNRR-UHFFFAOYSA-N Mangostin Natural products CC(=CCc1c(O)cc2Oc3cc(C)c(O)c(CC=C(C)C)c3C(=O)c2c1O)C QTDMGAWIBXJNRR-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 201000006966 adult T-cell leukemia Diseases 0.000 description 3
- ZVFQDLCERPGZMO-UHFFFAOYSA-N alpha-mangostin Natural products OC1=C(CC=C(C)C)C(O)=C2C(=O)C3=C(CC=C(C)C)C(OC)=C(O)C=C3CC2=C1 ZVFQDLCERPGZMO-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000006552 constitutive activation Effects 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- TXZJFHOZUHJSHB-UHFFFAOYSA-N 1,3,5,6-tetrahydroxyxanthone Natural products Oc1cc(O)c2Oc3ccc(O)c(O)c3C(=O)c2c1 TXZJFHOZUHJSHB-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010034156 Pathological fracture Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- -1 xanthone compound Chemical class 0.000 description 2
- JFRMYMMIJXLMBB-UHFFFAOYSA-N xanthydrol Chemical compound C1=CC=C2C(O)C3=CC=CC=C3OC2=C1 JFRMYMMIJXLMBB-UHFFFAOYSA-N 0.000 description 2
- BWODNRWGBLRZJI-UHFFFAOYSA-N (2,3,4,5,6-pentamethoxyphenyl)-phenylmethanone Chemical compound COC1=C(OC)C(OC)=C(OC)C(OC)=C1C(=O)C1=CC=CC=C1 BWODNRWGBLRZJI-UHFFFAOYSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- HXBPZVYUSHEUKY-UHFFFAOYSA-N 3,6-dihydroxy-1-(hydroxymethoxy)xanthen-9-one Chemical compound C1=CC2=C(C=C1O)OC3=C(C2=O)C(=CC(=C3)O)OCO HXBPZVYUSHEUKY-UHFFFAOYSA-N 0.000 description 1
- ZTGSICGSZVMZDH-UHFFFAOYSA-N 4-[1-(2-amino-5-chloropyrimidin-4-yl)-2,3-dihydroindol-6-yl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)but-3-yn-2-ol Chemical compound CC1=NOC(C(C)(O)C#CC=2C=C3N(CCC3=CC=2)C=2C(=CN=C(N)N=2)Cl)=N1 ZTGSICGSZVMZDH-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 description 1
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 0 CC(C1)(C([C@@]2O[C@](C*)[C@@](*)[C@](*)[C@]2*)=C(*)C(C(c2c3)=O)=C1Oc2cc(O)c3O)O Chemical compound CC(C1)(C([C@@]2O[C@](C*)[C@@](*)[C@](*)[C@]2*)=C(*)C(C(c2c3)=O)=C1Oc2cc(O)c3O)O 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 206010056663 Gastric infection Diseases 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 description 1
- 101000978570 Homo sapiens Noelin Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 description 1
- 102100023731 Noelin Human genes 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 208000010572 basal-like breast carcinoma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- BMZWBEHLBROZOP-UHFFFAOYSA-N c1n[nH]cc1-c1c[nH]c2cnccc12 Chemical class c1n[nH]cc1-c1c[nH]c2cnccc12 BMZWBEHLBROZOP-UHFFFAOYSA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HHRZAEJMHSGZNP-UHFFFAOYSA-N mebanazine Chemical compound NNC(C)C1=CC=CC=C1 HHRZAEJMHSGZNP-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 108091070778 miR-520e stem-loop Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000008779 noncanonical pathway Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
マンギフェリン8aは、原料となる1,3,2’,3’,4’,6,6’,7−オクタ−O−プロピオニルマンギフェリンを合成し、それを元にさらに合成する2段階で得た。(1)1,3,2’,3’,4’,6,6’,7−オクタ−O−プロピオニルマンギフェリンの合成
13C−NMR(200MHz,DMSO−d6)δ:8.68/8.77/8.79/8.92/8.95/8.98/9.00/9.01/9.04/9.06/9.17/9.19/9.28 (COCH2CH3), 26.6/26.7/26.9/26.8/26.93/26.97/27.00/27.09/27.35/27.37 (COCH2CH3), 62.1/62.2 (C6’),68.20/68.23 (C4’), 69.6/70.1(C2’), 70.9/71.3(C1’), 73.6/73.7 (C3’), 75.06/75.10 (C5’), 110.3/111.8 (C4), 111.7/112.6 (C9a), 113.3/113.4 (C5), 118.9/119.0 (C2), 119.7/119.7 (C8a), 120.36/120.40 (C8), 139.57/139.59 (C7’), 147.9 (C6), 149.1/150.9 (C1), 152.5/152.6 (C8b), 153.4/154.8 (C4a), 156.6/156.8 (C3), 171.09/171.13/171.15/171.20/171.72/171.79/171.82/171.93/172.37/172.44/172.78/172.87/173.16/173.23/173.26 (COCH2CH3), 173.56/173.60 (C9).
HRMS (FAB) m/z: [M+Na]+ Calcd for C43H5 0O19Na 893.2844; Found 893.2883.
1,3,2’,3’,4’,6,6’,7−オクタ−O−プロピオニルマンギフェリン(3.7g,4.25mmol)、酢酸アンモニウム(3.8g,49.4mmol)、メタノール(80mL)および水(40mL)の混合溶液を室温で5.5時間撹拌した。反応液から減圧濃縮によりメタノールを留去した後、残渣を酢酸エチル(100mL)で希釈した。その混合物を、水および飽和食塩水で順次洗浄後、無水硫酸ナトリウムで乾燥後、ろ過、濃縮した。残渣をカラムクロマトグラフィー[CHCl3/CH3OH(20:1)]を用いて精製して得た淡黄色固体(2.54g)をメタノール(80mL)に溶解し、活性炭で脱色して(1)式のマンギフェリン8a(2.16g,73%)を無色固体として得た。
13C−NMR(200MHz,DMSO−d6)δ::8.84/8.89/9.00/9.05/9.10/9.14/9.15/9.21/9.23 (COCH2CH3), 26.7/26.92/26.96/26.98/27.04/27.08/27.12/27.4 (COCH2CH3), 62.1/62.4 (C−6’), 68.2/68.4 (C−4’), 68.8/70.5 (C−2’), 71.0/71.1 (C−1’), 73.8/74.2 (C−3’), 74.7/75.3 (C−5’), 99.6/100.8 (C−4), 102.50/102.52 (C−5), 106.6/107.7 (C−9a), 109.1 (C−8), 113.4 (C−2), 114.0/114.1 (C−8a), 143.87/143.88 (C−7), 149.83/149.89 (C−6), 151.3 (C−1), 153.4 (C−8b), 157.6/157.7 (C−4a), 161.0/162.4 (C−3), 171.2/172.0/172.3/172.9/173.2/173.5/173.6 (COCH2CH3) 172.7/172.8 (C−9).
HRMS (FAB)m/z:[M+Na]+ Calcd for C34H38NaO16 725.2058; Found. 725.2074.
ノラチリオールを非特許文献38の方法に従って合成した。
本実施例に示す合成方法を簡単に説明すると次のとおりである。すなわち、文献記載(非特許文献38)の方法に従って、2,4,5−トリメトキシ安息香酸(化合物II)を塩化チオニルで処理して2,4,5−トリメトキシ安息香酸クロリド(化合物III)を得た。次に、得られた化合物(化合物III)と1,3,5−トリメトキシベンゼン(化合物IV)とのフリーデル−クラフト反応により2−ヒロドキシ−2’,4,4’,5,6’−ペンタメトキシベンゾフェノン(化合物V)を得た。さらに、この化合物(V)にテトラブチルアンモニウムヒドロキシドを処理して、1,3,6,7−テトラメトキシキサントン(化合物VI)を得、その後、脱メチル化を行い、ノラチリオール(化合物I)を収率39%で得た。
(1)2,4,5−トリメトキシ安息香酸クロリド(化合物III)の製造方法
2,4,5−トリメトキシ安息香酸(化合物II、8.49g、0.040mol)にアルゴン雰囲気下、室温で塩化チオニル(5mL)を徐々に加えて溶解させたのち、6時間加熱還流を行った。反応終了後、反応混合物を減圧下留去し、2,4,5−トリメトキシ安息香酸クロリド(化合物III、8.30g、90%)を得た。得られた化合物(III)は、ただちに次の反応へ用いた。
上述のようにして得られた2,4,5−トリメトキシ安息香酸クロリド(化合物III、8.07g、0.035mol)、1,3,5−トリメトキシベンゼン(化合物IV、6.48g、0.0385mol)および無水ジエチルエーテル(500mL)の混合懸濁物にアルゴン雰囲気下、室温で塩化アルミニウム(16g)を徐々に加えた後、反応混合物を室温で48時間攪拌した。反応液を減圧下溶媒留去した後、残渣に水を加え、酢酸エチルにて抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=1:1,v/v)により精製し、2−ヒロドキシ−2’,4,4’,5,6’−ペンタメトキシベンゾフェノン(化合物V、8.43g、69%)を得た。
上述のようにして得られた2−ヒロドキシ−2’,4,4’,5,6’−ペンタメトキシベンゾフェノン(化合物V、6.97g、0.020mol)をピリジン(10mL)と水(10mL)との混合溶媒を溶かし、40%テトラブチルアンモニウムヒドロキシド水溶液(5mL)を加えて6時間加熱還流を行った。得られた反応混合物を5%塩酸に注加した後、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(n−ヘキサン:酢酸エチル=1:1,v/v)により精製し、1,3,6,7−テトラメトキシキサントン(化合物VI、5.82g、92%)を得た。
上述のようにして得られた1,3,6,7−テトラメトキシキサントン(化合物VI、4.74g、0.015mol)とピリジン塩酸塩(5.00g)の混合物を6時間、200℃にて加熱攪拌した。得られた反応混合物を室温まで放冷後、5%塩酸に注加した後、酢酸エチルで抽出した。抽出液を飽和食塩水で洗浄後、無水硫酸ナトリウムで乾燥し、ひだ折りろ紙にて乾燥剤を濾別後、ろ液を減圧下溶媒留去して粗生成物を得た。得られた粗生成物をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=7:1,v/v)により精製し、(2)式のノラチリオール(化合物I、2.65g、68%)を得た。
Raji細胞(悪性リンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。Raji細胞を96−well
plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図2に示す。
CCRF−SB細胞(悪性リンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。CCRF−SB細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図3に示す。
Namalwa細胞(悪性リンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。Namalwa細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図4に示す。
Z138細胞(悪性リンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。Z138細胞を96−well
plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図5に示す。
SU−DHL−5細胞(悪性リンパ腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。SU−DHL−5細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図6に示す。
L363細胞(多発性骨髄腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。L363細胞を96−well
plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図7に示す。
KMS−28BM細胞(多発性骨髄腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。KMS−28BM細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図8に示す。
ARH77細胞(多発性骨髄腫腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。ARH77細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図9に示す。
IM9細胞(多発性骨髄腫腫細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。IM9細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図10に示す。
RPMI1788細胞(正常Bリンパ球細胞株)は5%CO2、37℃の条件下で、培養を行った。培養液はRPMI−1640培地に100μg/mLペニシリン、100U/mLストレプトマイシンとウシ胎児血清を添加したものを用いた。RPMI1788細胞を96−well plateに播種後、各濃度の薬剤を添加し、トリパンブルーダイ法により細胞生存率を測定した。結果を図11に示す。
IM9細胞を用いて各薬剤投与によるNIK阻害作用について、イムノブロテッィングで検討した結果、NIK活性化阻害作用を認めた(図12)。
ノラチリオール、10μM メトキシキサントン、50μM テトラヒドロキシキサントン、Control、10μM キサントヒドロール、50μM α−マンゴスチン、50μM γ−マンゴスチンを添加された場合を並べて示した。
各薬剤投与により、NIKの下流シグナルであるIKK、NF−κB p52、NF−κB p65の活性化動態について検討した結果、IKKの活性阻害、NF−κB p52およびNF−κB p65の核移行阻害を認めた(図13)。
ノラチリオール、10μM メトキシキサントン、50μM テトラヒドロキシキサントン、Control、10μM キサントヒドロール、50μM α−マンゴスチン、50μM γ−マンゴスチンを添加された場合を並べて示した。
L363細胞を用いて各薬剤投与によるCD138発現抑制作用について、Flow cytometryで検討した結果、CD138発現抑制作用を認めた。
L363細胞を用いて各薬剤投与によるCD20発現増加作用について、Flow cytometryで検討した結果、CD20発現増加作用を認めた。
L363細胞を用いて各薬剤投与によるIgG分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、IgG分泌抑制作用を認めた。
L363細胞を用いて各薬剤投与による免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用を認めた。
L363細胞を用いて各薬剤投与による骨破壊関連因子の分泌抑制作用について、Luminexで検討した結果、骨破壊関連因子の分泌抑制作用を認めた。
KMS−28BM細胞を用いて各薬剤投与によるCD138発現抑制作用について、Flow cytometryで検討した結果、CD138発現抑制作用を認めた。
KMS−28BM細胞を用いて各薬剤投与によるCD20発現増加作用について、Flow cytometryで検討した結果、CD20発現増加作用を認めた。
KMS−28BM細胞を用いて各薬剤投与によるIgG分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、IgG分泌抑制作用を認めた。
KMS−28BM細胞を用いて各薬剤投与による免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用について、酵素結合免疫吸着測定法(ELISA)で検討した結果、免疫グロブリン遊離軽鎖のλ鎖の分泌抑制作用を認めた。
KMS−28BM細胞を用いて各薬剤投与による骨破壊関連因子の分泌抑制作用について、Luminexで検討した結果、骨破壊関連因子の分泌抑制作用を認めた。
Raji細胞をNOD/ShiJic−scidJclマウスに移植し、ノラチリオールを経口投与した場合の腫瘍増殖抑制作用について検討した結果、顕著な腫瘍増殖抑制作用を認めた。
L363細胞をNOD/ShiJic−scidJclマウスに移植し、ノラチリオールを経口投与した場合の腫瘍増殖抑制作用について検討した結果、顕著な腫瘍増殖抑制作用を認めた。
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019021877 | 2019-02-08 | ||
JP2019021877 | 2019-02-08 | ||
PCT/JP2020/005170 WO2020162638A1 (ja) | 2019-02-08 | 2020-02-10 | 悪性腫瘍疾患の改善用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2020162638A1 true JPWO2020162638A1 (ja) | 2021-12-16 |
Family
ID=71947219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020571319A Pending JPWO2020162638A1 (ja) | 2019-02-08 | 2020-02-10 | 悪性腫瘍改善用組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2020162638A1 (ja) |
WO (1) | WO2020162638A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240124430A1 (en) * | 2020-12-22 | 2024-04-18 | Kinki University | Pharmaceutical composition for ameliorating malignant diseases |
US20240115589A1 (en) * | 2021-02-15 | 2024-04-11 | Kinki University | Pharmaceutical composition for preventing cytokine storm |
CN115120725B (zh) * | 2022-05-30 | 2023-11-07 | 南方医科大学 | Sdc1作为骨质破坏疾病药物治疗靶点的应用 |
CN115340519B (zh) * | 2022-07-22 | 2023-07-18 | 广西仙茱中药科技有限公司 | 苯骈色原酮化合物的制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5140231B2 (ja) * | 2004-04-08 | 2013-02-06 | 株式会社ロッテ | IκBキナーゼ阻害剤 |
WO2011034772A1 (en) * | 2009-09-16 | 2011-03-24 | The University Of Toledo | Na/k-atpase ligands, ouabain antagonists, assays and uses thereof |
CN101889998B (zh) * | 2010-05-28 | 2012-10-03 | 暨南大学 | 一种组合物及其在制备tr3受体诱导剂中的应用 |
CN102432602B (zh) * | 2011-10-24 | 2014-07-02 | 广西中医药大学 | 芒果苷七丙酯化衍生物 |
CA2985787A1 (en) * | 2012-06-07 | 2013-12-12 | Georgia State University Research Foundation, Inc. | Seca inhibitors and methods of making and using thereof |
TWI627173B (zh) * | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物 |
KR101658586B1 (ko) * | 2015-02-25 | 2016-09-21 | 원광대학교산학협력단 | 알파 또는 감마 망고스틴을 유효성분으로 함유하는 췌장암의 예방, 개선 또는 치료를 위한 조성물 |
JP6488264B2 (ja) * | 2015-07-30 | 2019-03-20 | 学校法人近畿大学 | Nik阻害剤 |
CN109053670A (zh) * | 2018-07-19 | 2018-12-21 | 中国药科大学 | 一种磷酸甘油酸变位酶1抑制剂及其在相关疾病中的应用 |
-
2020
- 2020-02-10 WO PCT/JP2020/005170 patent/WO2020162638A1/ja active Application Filing
- 2020-02-10 JP JP2020571319A patent/JPWO2020162638A1/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020162638A1 (ja) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020162638A1 (ja) | 悪性腫瘍疾患の改善用組成物 | |
JP7479695B2 (ja) | 自己免疫疾患の改善用組成物 | |
KR101674145B1 (ko) | 데쿠르시놀 카바메이트 유도체, 및 이를 포함하는 암 예방 또는 치료용 약학적 조성물 | |
WO2022138735A1 (ja) | 悪性腫瘍疾患の改善用医薬組成物 | |
KR101388635B1 (ko) | 다프난 다이터페노이드(Daphnane diterpenoid)계 물질의 상피세포 성장인자 수용체(EGFR) 저해제인 제피티닙(Gefitnib) 내성 인간 폐암 세포에 유용한 항암제 | |
CN107438433B (zh) | 含2-甲氧基-4-(3-(4-甲氧基苯基)丙-1-烯-1-基)苯酚作为活性成分的防治关节炎或炎性疾病的药物组合物 | |
JPWO2005074906A1 (ja) | 治療剤 | |
CN112513000B (zh) | 新型联苯衍生物化合物及其用途 | |
Wang et al. | Garcinol and its analogues: Synthesis, cytotoxic activity and mechanistic investigation | |
KR101924801B1 (ko) | 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 | |
JP2022003034A (ja) | 藻類プロテオグリカン抽出物含有組成物及びその使用 | |
WO2022173042A1 (ja) | サイトカインストーム抑制用医薬組成物 | |
CN110996930B (zh) | 新型亚苄基丙酮衍生物及其用途 | |
KR101724425B1 (ko) | (z)―2―아세트아미도―3―(4―히드록시―3―메톡시페닐)아크릴산을 유효성분으로 포함하는 암 예방 또는 치료용 조성물 | |
KR101325783B1 (ko) | 나프탈레닐페닐디히드로피라졸을 유효성분으로 포함하는 항암제 조성물 | |
KR101948555B1 (ko) | 수용체 티로신 키나아제 저해제를 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물 | |
KR102114197B1 (ko) | 신규한 벤질리덴아세톤 유도체 및 이의 용도 | |
KR101821498B1 (ko) | 브루소찰콘 a를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물 | |
US20240115537A1 (en) | Composition for preventing or treating breast cancer comprising compound derived from dendropanax morbiferus | |
CN112512999A (zh) | 新型联苯衍生物化合物及其用途 | |
KR101697062B1 (ko) | 물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물 | |
WO2018062895A1 (ko) | 오스문드아세톤 또는 이의 약학적으로 허용가능한 염을 포함하는 골 질환 예방 또는 치료용 조성물 | |
JP6841427B2 (ja) | スクレロスチンを用いた悪性骨腫瘍の治療又は予防 | |
Haaften et al. | Synthesis of EPD, an established cytotoxic agent for ovarian cancer cells, and its efficacy in cisplatin and paclitaxel resistant tumor cells | |
KR20230032983A (ko) | 베르베논 유도체를 포함하는 비만 또는 비만-관련 간질환의 치료 또는 예방용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221024 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230822 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240308 |